Key Developments: VIVUS Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

2.33USD
29 Jun 2015
Change (% chg)

-- (--)
Prev Close
$2.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
259,580
52-wk High
$5.45
52-wk Low
$2.22

Search Stocks

Latest Key Developments (Source: Significant Developments)

Vivus files lawsuit against Teva for infringement of Qsymia Patents
Wednesday, 15 Apr 2015 07:30pm EDT 

Vivus Inc:Files a lawsuit in the U.S. District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd., collectively referred to as Teva.Lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Teva.VIVUS filed the lawsuit on the basis that Teva's proposed generic products infringe each of these patents held by VIVUS.  Full Article

VIVUS Inc appoints CFO - Form 8-K
Tuesday, 13 Jan 2015 04:06pm EST 

VIVUS Inc:Says on Jan. 7, 2015, it determined to remove the interim from Sanford’s title, such that Sanford’s title became chief financial officer and chief accounting officer effective Jan. 7, 2015.  Full Article

VIVUS Inc announces issuance of two additional U.S. Patents
Wednesday, 26 Nov 2014 07:00am EST 

VIVUS Inc:The United States Patent and Trademark Office has issued U.S. Patent Nos. 8,895,057 covering methods for effecting weight loss using Qsymia, and 8,895,058 covering compositions of Qsymia.  Full Article

Vivus and Auxilium announce FDA approval of STENDRA sNDA
Thursday, 18 Sep 2014 06:00am EDT 

Vivus Inc and Auxilium Pharmaceuticals Inc:Says U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA A (avanafil).  Full Article

Vivus announces acquisition of Topiramate-related Patents from Janssen Pharmaceuticals
Monday, 25 Aug 2014 07:00am EDT 

Vivus Inc:Says the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.Patents acquired includes U.S. 6,071,537 (Shank), U.S. 6,362,220 (Cottrell) and others -- are directed to methods of using topiramate to treat obesity, lower blood pressure and lipid parameters, and reduce blood glucose.  Full Article

Vivus files lawsuit against actavis for infringement of Qsymia Patents
Thursday, 12 Jun 2014 04:32pm EDT 

Vivus Inc:Files a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis.Lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis.Actavis seeks to market and sell generic versions of the currently approved doses of Qsymia capsules CIV prior to the expiration of U.S.  Full Article

Vivus Inc collaborates with aetna to test first comprehensive weight management program integrating weight loss medication
Tuesday, 14 Jan 2014 07:00am EST 

Vivus Inc:Says it has joined with Aetna to integrate Qsymia (phentermine and topiramate extended-release) capsules CIV into a pilot program designed to evaluate the benefits of prescription medication combined with lifestyle support for weight loss.Says the program is the first of its kind involving Qsymia and a health care benefits provider.  Full Article

Vivus Inc announces license and commercialization agreement with Sanofi SA
Thursday, 12 Dec 2013 07:07am EST 

Vivus Inc:Says it has entered into a license and commercialization agreement with Sanofi SA to commercialize avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia.Says Sanofi will be responsible for obtaining regulatory approval in its territories.Sanofi intends to market avanafil under the tradename SPEDRA or STENDRA.Under the terms of the agreement, Vivus is eligible to receive up to $61 million in upfront payments, regulatory and sales milestones and will also receive escalating royalties based on net sales over the life of the agreement.  Full Article

Vivus Inc Announces Issuance of Two Key U.S. Patents for Qsymia
Wednesday, 13 Nov 2013 07:00am EST 

Vivus Inc announced that the United States Patent and Trademark Office has issued U.S. Patent Nos. 8,580,298 covering compositions of Qsymia, and 8,580,299, covering methods for effecting weight loss using Qsymia. The newly issued patents are assigned to VIVUS and are an addition to the existing foundational patents - listed in the U.S. Food & Drug Administration (FDA) Orange Book - that provide market exclusivity for Qsymia. Prior to issuance of these new patents, patent protection for Qsymia in the U.S. was expected to expire in June 2020. With the addition of the two new patents, both of which have been submitted for listing in the FDA Orange Book, patent exclusivity for Qsymia in the U.S. is expected to extend to June 2029.  Full Article

Vivus Inc Announces Appointment Of Interim CFO - Form 8-K
Tuesday, 5 Nov 2013 04:06pm EST 

Vivus Inc reported in its Form 8-K that on November 5, 2013, the Board of Directors of the Company appointed Svai Sanford, the Company’s Corporate Controller, as interim Chief Financial Officer (CFO) effective November 5, 2013, or the Effective Date. As of the Effective Date, Mr. Sanford has assumed the duties of the Company’s principal financial officer on an interim basis.  Full Article

Actavis, Vivus clash over in-house counsel role in patent fight

- A U.S. subsidiary of Actavis PLC and rival drugmaker Vivus Inc have asked a federal judge to weigh in on a dispute over whether a Vivus in-house attorney should be allowed to work on a patent lawsuit over Vivus' weight-loss drug Qsymia and on other matters related to that drug at the same time.

Search Stocks